Pauci-immune glomerulonephritis
MONDO:0019641Pauci-immune glomerulonephritis (GN) is one of the most frequent causes of rapidly progressive GN (RPGN). It is characterized clinically by renal manifestations of RPGN (hematuria, hypertension) leading to renal failure within days or weeks, and may be associated with manifestations of systemic vasculitis (arthralgia, fever, seizures, mono neuritis and lung involvement). Pauci-immune GN is histologically characterized by focal necrotizing and crescentic GN, with mild or absent glomerular staining for immunoglobulin and complement by fluorescence microscopy, which may manifest either as part of a systemic small vessel vasculitis (including microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis), or rarely as part of renal-limited vasculitis (RLV, idiopathic crescentic GN). Immunologic classification is based on the presence or absence of circulating anti-neutrophil cytoplasmic antibodies (ANCAs), namely pauci-immune-GN with ANCA and pauci-immune GN without ANCA.
8 clinical trials for this condition and its sub-types, 1 tagged with Pauci-immune glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pauci-immune glomerulonephritis
-
Can a targeted antibody tame kidney inflammation without heavy steroids?
Disease control Recruiting nowThis phase 2 trial is testing whether a new drug called obinutuzumab beta, combined with a short course of steroids, can help people with newly diagnosed ANCA-associated glomerulonephritis—a rare autoimmune disease that causes kidney inflammation and damage. The study will enroll…
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on lupus and more
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New ultrasound technique could spare kidney patients from biopsies
Knowledge-focused Recruiting nowThis study is testing a new ultrasound method to look at tiny blood vessels in the kidneys of people with nephritis (kidney inflammation). Researchers will use contrast-enhanced ultrasound and ultrasound localization microscopy to create detailed images of kidney blood flow. The …
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC